Wells Fargo lowered the firm’s price target on Inari Medical to $84 from $100 and keeps an Overweight rating on the shares. The firm notes Inari reported Q1 sales that showed stabilization in core U.S. VTE growth. Management continues to see about 20% U.S. VTE market growth with Inari to remain the market leader, raising guidance, says Wells.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI:
- Inari Medical Reports First Quarter 2024 Financial Results
- Inari Medical management to meet with BTIG
- Inari Medical to Announce First Quarter 2024 Financial Results
- Inari Medical Announces the Release of 2023 Ethos and Sustainability Report
- Inari Medical Strengthens Senior Leadership Team with Addition of Two Executives